Valiant Laboratories Share Price | Valiant Laboratories Stock Screener
VALIANTLAB
Pharmaceuticals
Share Price NSE
₹79.62
▲
3.73 (4.92%)
Share Price BSE
₹64.52
▼
-1.29 (-1.96%)
As of April 28, 2026, the Valiant Laboratories share price (NSE: VALIANTLAB) is ₹79.62 on NSE and ₹64.52 on BSE, up 4.92% from the previous close, with shares trading between ₹77.27 and ₹81.00, and a 52-week range of ₹50.93–₹111.84.
Analyse VALIANTLAB share price history and track historical price performance.
Use the Valiant Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Valiant Laboratories Market Cap
₹353.03 Cr.
VALIANTLAB P/E Ratio (TTM)
-110.93
Valiant Laboratories P/B Ratio
1.16
EPS (TTM)
₹-0.51
Dividend Yield
-
Debt to Equity
0.42
VALIANTLAB 52 Week High
₹111.84
Valiant Laboratories 52 Week Low
₹50.93
Operating Margin
5.00%
Profit Margin
2.17%
VALIANTLAB Revenue (TTM)
₹92.00
EBITDA
₹5.00
Net Income
₹2.00
Total Assets
₹464.00
Total Equity
₹311.00
Valiant Laboratories Share Price Chart
Screen Valiant Laboratories share price with an interactive chart. Analyse VALIANTLAB price trends and volatility across different timeframes.
Valiant Laboratories Company Profile - Fundamental Screener
Screen Valiant Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for VALIANTLAB shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE0JWS01017
Valiant Laboratories Balance Sheet Screener
Screen VALIANTLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Assets | ||||
| Total Assets | 464 | 401 | 343 | 213 |
| Current Assets | 228 | 193 | 226 | 151 |
| Fixed Assets | 233 | 48 | 50 | 48 |
| Liabilities | ||||
| Total Liabilities | 0 | 0 | 0 | 0 |
| Current Liabilities | 34 | 107 | 77 | 62 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||
| Total Equity | 311 | 234 | 237 | 101 |
| Share Capital | 54 | 44 | 44 | 33 |
| Reserves & Surplus | 257 | 191 | 193 | 68 |
Valiant Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Valiant Laboratories income statement and profit fundamentals.
Analyze VALIANTLAB quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Valiant Laboratories share price evaluation.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 92 | 53 | 47 | 48 | 56 | 37 | 25 | 22 | 33 | 42 | 63 | 54 | 92 | 72 | 84 |
| Expenses | 87 | 53 | 46 | 44 | 54 | 35 | 28 | 21 | 35 | 47 | 61 | 48 | 81 | 61 | 79 |
| EBITDA | 5 | 0 | 1 | 3 | 2 | 2 | -3 | 0 | -2 | -5 | 2 | 6 | 10 | 11 | 4 |
| Operating Profit % | 5.00% | -2.00% | 0.00% | 5.00% | 7.00% | 2.00% | -31.00% | -13.00% | -15.00% | -16.00% | -2.00% | 7.00% | 10.00% | 14.00% | 5.00% |
| Depreciation | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | -3 | 0 | 3 | 1 | 2 | -4 | 0 | -3 | -5 | 1 | 6 | 10 | 10 | 4 |
| Tax | -1 | 4 | 0 | 1 | 0 | -1 | 1 | 0 | -1 | -2 | 0 | 2 | 2 | 3 | 1 |
| Net Profit | 2 | -7 | 0 | 2 | 1 | 2 | -5 | -1 | -1 | -4 | 1 | 4 | 8 | 8 | 3 |
| EPS | 0.32 | -1.30 | 0.04 | 0.42 | 0.16 | 0.54 | -1.09 | -0.13 | -0.33 | -0.81 | 0.24 | 1.31 | 2.41 | 4.70 | 1.65 |
Valiant Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen VALIANTLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March |
|---|---|---|---|
| Operating Activities | 1 | 2 | 56 |
| Investing Activities | -53 | -144 | -55 |
| Financing Activities | 45 | 152 | -1 |
| Net Cash Flow | -7 | 11 | 0 |
Valiant Laboratories Shareholding Pattern Screener
See Valiant Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Valiant Laboratories promoter holding and ownership changes for VALIANTLAB on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Aug | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% |
| FII Holding | 0.20% | 0.64% | 0.63% | 0.52% | 0.02% | 0.01% | 3.48% | 1.89% |
| DII Holding | 0.00% | 0.00% | 0.46% | 0.00% | 0.00% | 0.00% | 0.03% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 18.53% | 16.28% | 17.05% | 17.08% | 18.19% | 18.51% | 15.16% | 16.09% |
| Other Holding | 6.33% | 8.13% | 6.92% | 7.46% | 6.85% | 6.55% | 6.39% | 7.07% |
| Shareholder Count | 14,657 | 15,036 | 14,432 | 14,948 | 15,075 | 14,910 | 14,914 | 14,249 |
Valiant Laboratories Share Dividend Screener - Share Yield Analysis
Check Valiant Laboratories dividend history with payout and yield data.
View Valiant Laboratories dividend details including ex-dates and amounts for VALIANTLAB stock.
Valiant Laboratories Stock Index Membership
See which indices include Valiant Laboratories stock.
Check VALIANTLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Valiant Laboratories Market Events Screener - Corporate Actions
Get Valiant Laboratories corporate actions including splits, bonuses, and buybacks.
Check Valiant Laboratories stock events that may affect VALIANTLAB share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 1.55% | ||
| 2026-05-14 | 2026-05-14 | Quarterly Result Announcement | NA | -1.81% |
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 8.90% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | -1.09% |
| 2025-08-08 | 2025-08-08 | Quarterly Result Announcement | NA | 3.60% |
| 2025-07-18 | 2025-07-19 | Rights | 1:4 | -1.43% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 3.47% |
| 2025-02-07 | 2025-02-07 | Quarterly Result Announcement | NA | 6.48% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | -3.59% |
| 2024-08-08 | 2024-08-08 | Annual General Meeting | NA | -13.18% |
Valiant Laboratories Competitors Screener - Peer Comparison
Screen VALIANTLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 446,876 | 39.04 | 58,220 | 6.38% | 11,565 | 60.32 |
| Divis Laboratories | 174,652 | 67.84 | 10,560 | 8.73% | 2,520 | 44.73 |
| Torrent Pharmaceuticals | 156,365 | 73.76 | 13,886 | 20.34% | 2,138 | 62.27 |
| Cipla | 118,382 | 30.41 | 29,045 | 2.24% | 3,870 | 69.96 |
| Dr Reddys Laboratories | 113,273 | 27.63 | 33,593 | -0.44% | 3,998 | 66.21 |
| Zydus Life Science | 111,954 | 22.03 | 26,720 | 13.65% | 5,242 | 62.64 |
| Lupin | 110,605 | 20.55 | 27,488 | 19.98% | 5,345 | 68.05 |
| Mankind Pharma | 105,132 | 52.96 | 14,278 | 12.03% | 1,750 | 64.79 |
| Aurobindo Pharma | 90,835 | 25.68 | 33,385 | 3.21% | 3,376 | 69.05 |
| Laurus Labs | 81,918 | 91.20 | 6,868 | 22.01% | 890 | 72.35 |
Valiant Laboratories Company Announcements - News Screener
Screen VALIANTLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-07-03 | Closure of Trading Window | - |
| 2026-05-30 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-05-22 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-20 | Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011 | - |
| 2026-05-19 | Intimation Recieved Under Regulation 10(5) Of SEBI (SAST) Regulations 2011 | - |
| 2026-05-16 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-16 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-14 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-05-14 | Audited Standalone And Consolidated Financial Results For Quarter And Year Ended March 31 2026. | - |
| 2026-05-14 | Appointment Of Cost Auditor And Internal Auditor | - |
| 2026-05-14 | Audited Standalone And Consolidated Financial Results For Quarter And Year Ended March 31 2026. | - |
| 2026-05-14 | Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For Quarter And Year Ended March 31 2026. | - |
| 2026-05-11 | Board Meeting Intimation for Approval Of Financial Results For Quarter And Year Ended March 31 2026 | - |
| 2026-04-23 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-04-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-26 | Closure of Trading Window | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-11 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-02-11 | Audited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31 2025. | - |
| 2026-02-11 | Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31 2025. | - |